It is possible that VEGF released by TACE‐induced hypoxia is inhibited by lenvatinib, a multikinase inhibitor, by inhibiting the VEGF receptor, leading to the reprogramming of the immunosuppressive tumor microenvironment into an immunostimulatory environment and enhancing the immune regulatory activity of PD‐1 inhibitor in HCC.29 The gene discussed is VEGFA; the disease is hepatocellular carcinoma.